Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2011

View Archived Issues

Phase II trial evaluates anakinra in patients with subarachnoid hemorrhage

Phase III data show benefits of azilsartan medoxomil potassium/chlorthalidone in hypertension

ATROSAB reduces disease symptoms in monkeys with arthritis

Phase II data presented on AZD-9668 in cystic fibrosis

Phase I trial evaluates ciprofloxacin dry powder inhaler in COPD

GSK claims new bromodomain-containing protein inhibitors

Novel lactam tachykinin receptor antagonists presented

New Toll-like receptor 7 agonists disclosed by IRM

Piramal Life Sciences discloses novel imidazopyridines

Merck KGaA patents new TGF-beta receptor type-1 inhibitors

Generex enters agreement to license RapidMist technology to Amarantus BioSciences

EMA accepts Pfizer's regulatory filing for axitinib in renal cell carcinoma

FDA grants priority review to Alexion's Soliris sBLA for atypical hemolytic uremic syndrome

D-Pharm forms agreement with Jiangsu Nhwa Pharmaceutical for DP-VPA in China

FDA clears Fujirebio Diagnostics' CYFRA 21-1 assay for monitoring lung cancer

Health Canada approves new indication for Gardasil

EMA to review Gentium's MAA for defibrotide under accelerated assessment

AcelRx receives U.S. army grant for phase II development of ARX-04 for acute pain

CrystalGenomics begins phase IIb trial of CG-100649 in osteoarthritis

COMP issues opinion on orphan drug of CYT-387 in myelofibrosis

European approval for Yellox as therapy for postoperative ocular inflammation

Nuvilex reports encouraging phase II data on new treatment for pancreatic cancer

Adaptimmune begins phase I/II trial of T-cell therapy in multiple myeloma

HIV-1 vaccine candidate rVSVIN-N4CT9-Gag1 enters phase I trial

Ferring and Kyowa Hakko Kirin conclude copromotion agreement for desmopressin tablets in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....